Stock listing
LSE:0Q77 AB Science SA Share Price
UK listing (LSE) of AB Science SA · home listing Euronext:AB
Follow AB Science SA into a list and get an email when it puts out news.
Share price · LSE:0Q77
€0.546 EUR -0.021 (-3.7%)
Close on Nov 20, 2026
- Day range
- €0.546 – €0.546 EURNov 20, 2026
- Volume
- 2 sharesNov 20, 2026
- Market cap
- €47.41M EURAt the close on Nov 20, 2026 · price × 86.83M shares outstanding
- 52-week range
- €0.508 – €1.580 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,579 EURMedian day 73 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:AB · Home | €0.521 EUR | -0.043 (-7.6%) | 99,512 | €0.562 | €0.562 | €0.520 | €0.564 | Close on Nov 20, 2026 |
| LSE:0Q77 | €0.546 EUR | -0.021 (-3.7%) | 2 | €0.546 | €0.546 | €0.546 | €0.567 | Close on Nov 20, 2026 |
| Frankfurt:A8D | €0.555 EUR | -0.012 (-2.1%) | — | €0.555 | €0.555 | €0.555 | €0.567 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0Q77 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.525 | -0.004 | -0.8% | €0.525 | €0.525 | €0.525 | 4 | |
| €0.529 | -0.001 | -0.2% | €0.528 | €0.530 | €0.527 | 10,450 | |
| €0.530 | 0.000 | 0.0% | €0.530 | €0.536 | €0.530 | 32 | |
| €0.530 | -0.015 | -2.8% | €0.538 | €0.538 | €0.530 | 200 | |
| €0.545 | -0.009 | -1.6% | €0.545 | €0.545 | €0.545 | 2 | |
| €0.554 | 0.000 | 0.0% | €0.554 | €0.554 | €0.554 | 0 | |
| €0.554 | +0.013 | +2.4% | €0.554 | €0.554 | €0.554 | 78 | |
| €0.541 | +0.011 | +2.1% | €0.541 | €0.541 | €0.541 | 2,623 | |
| €0.530 | -0.017 | -3.1% | €0.533 | €0.533 | €0.530 | 61 | |
| €0.547 | -0.005 | -0.9% | €0.541 | €0.547 | €0.541 | 4 | |
| €0.552 | -0.017 | -3.0% | €0.552 | €0.552 | €0.552 | 2 | |
| €0.569 | +0.004 | +0.7% | €0.569 | €0.569 | €0.569 | 7 | |
| €0.565 | +0.007 | +1.3% | €0.565 | €0.565 | €0.565 | 4 | |
| €0.558 | -0.007 | -1.2% | €0.558 | €0.558 | €0.558 | 2 | |
| €0.565 | +0.004 | +0.7% | €0.565 | €0.565 | €0.565 | 11 | |
| €0.561 | -0.020 | -3.4% | €0.561 | €0.561 | €0.561 | 4,999 | |
| €0.581 | +0.052 | +9.8% | €0.564 | €0.591 | €0.564 | 655 | |
| €0.529 | +0.008 | +1.5% | €0.526 | €0.529 | €0.526 | 46 | |
| €0.521 | +0.013 | +2.6% | €0.529 | €0.529 | €0.521 | 1,872 | |
| €0.508 | -0.025 | -4.7% | €0.522 | €0.522 | €0.508 | 8,297 | |
| €0.533 | -0.016 | -2.9% | €0.565 | €0.565 | €0.532 | 680 | |
| €0.549 | -0.003 | -0.5% | €0.570 | €0.570 | €0.549 | 74,029 | |
| €0.552 | -0.035 | -6.0% | €0.545 | €0.552 | €0.533 | 8,089 | |
| €0.587 | -0.005 | -0.8% | €0.587 | €0.587 | €0.587 | 10 | |
| €0.592 | -0.002 | -0.3% | €0.592 | €0.601 | €0.592 | 208 | |
| €0.594 | -0.002 | -0.3% | €0.605 | €0.605 | €0.594 | 131 | |
| €0.596 | -0.096 | -13.9% | €0.670 | €0.670 | €0.591 | 1,021 | |
| €0.692 | +0.025 | +3.7% | €0.690 | €0.692 | €0.690 | 3 | |
| €0.667 | -0.032 | -4.6% | €0.700 | €0.700 | €0.667 | 13,724 | |
| €0.699 | -0.011 | -1.5% | €0.711 | €0.711 | €0.699 | 17 | |
| €0.710 | -0.002 | -0.3% | €0.715 | €0.717 | €0.710 | 44 | |
| €0.712 | +0.002 | +0.3% | €0.720 | €0.720 | €0.712 | 93 | |
| €0.710 | +0.002 | +0.3% | €0.721 | €0.721 | €0.710 | 5 | |
| €0.708 | -0.002 | -0.3% | €0.708 | €0.708 | €0.708 | 117 | |
| €0.710 | -0.010 | -1.4% | €0.715 | €0.715 | €0.705 | 4,066 | |
| €0.720 | -0.013 | -1.8% | €0.730 | €0.730 | €0.720 | 63 | |
| €0.733 | +0.022 | +3.1% | €0.717 | €0.733 | €0.717 | 125 | |
| €0.711 | +0.006 | +0.9% | €0.711 | €0.711 | €0.711 | 5,384 | |
| €0.705 | -0.039 | -5.2% | €0.714 | €0.714 | €0.705 | 69 | |
| €0.744 | -0.001 | -0.1% | €0.744 | €0.744 | €0.744 | 8 | |
| €0.745 | +0.019 | +2.6% | €0.727 | €0.745 | €0.723 | 195 | |
| €0.726 | -0.010 | -1.4% | €0.743 | €0.743 | €0.720 | 1,768 | |
| €0.736 | +0.001 | +0.1% | €0.740 | €0.745 | €0.736 | 15 | |
| €0.735 | +0.018 | +2.5% | €0.731 | €0.759 | €0.731 | 2,520 | |
| €0.717 | +0.019 | +2.7% | €0.703 | €0.717 | €0.703 | 20 | |
| €0.698 | -0.031 | -4.3% | €0.708 | €0.708 | €0.698 | 153 | |
| €0.729 | -0.009 | -1.2% | €0.735 | €0.736 | €0.729 | 7 | |
| €0.738 | +0.023 | +3.2% | €0.738 | €0.738 | €0.738 | 5 | |
| €0.715 | -0.016 | -2.2% | €0.723 | €0.723 | €0.715 | 6 | |
| €0.731 | +0.065 | +9.8% | €0.675 | €0.774 | €0.675 | 2,188 | |
| €0.666 | -0.025 | -3.6% | €0.689 | €0.689 | €0.666 | 664 | |
| €0.691 | +0.004 | +0.6% | €0.700 | €0.700 | €0.681 | 66 | |
| €0.687 | -0.007 | -1.0% | €0.715 | €0.715 | €0.687 | 73 |
- Ticker
- LSE:0Q77
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- EUR
What changed lately
Latest news release · Oct 12, 2026
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6: 00 p.m. to 7: 30 p.m.
Latest deck · January 2026
Investor Presentation (January 2026)
Investor deck · 33 slides
Latest news
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6: 00 p.m. to 7: 30 p.m.
Oct 12, 2026
Closed €0.529 (+1.5%) on Oct 12, 2026
Revenues for the first half of 2026 and update on AB Science’s activities
Oct 9, 2026
Closed €0.529 (+1.5%) on Oct 12, 2026
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
Oct 9, 2026
Closed €0.529 (+1.5%) on Oct 12, 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
Sep 29, 2026
Closed €0.596 (-13.9%) on Sep 29, 2026
AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
Sep 29, 2026
Closed €0.596 (-13.9%) on Sep 29, 2026
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
Aug 16, 2026
Closed €0.716 (-1.9%) on Aug 17, 2026
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
Aug 10, 2026
Closed €0.74 (-19.7%) on Aug 10, 2026
AB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
Aug 9, 2026
Closed €0.74 (-19.7%) on Aug 10, 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
Jul 10, 2026
Closed €0.685 (-6.2%) on Jul 13, 2026
AB Science SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 51 in all · newest Oct 12, 2026 · oldest 2025
- Decks
- 21 decks · latest January 2026
Where AB Science SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:AB · Home listing | Euronext | France | EUR |
| LSE:0Q77 · This page | LSE | United Kingdom | EUR |
| LS Exchange:A1CXBG | LS Exchange | Germany | EUR |
| OTC:ABSCF | OTC | United States | USD |
| Lang & Schwarz:A1CXBG | Lang & Schwarz | Germany | EUR |
| gettex:A8D | gettex | Germany | EUR |
| Aquis:ABP | Aquis | United Kingdom | EUR |
| Turquoise:ABP | Turquoise | United Kingdom | EUR |
| Aquis:ABP | Aquis | United Kingdom | EUR |
| Dusseldorf:A8D | Dusseldorf | Germany | EUR |
| Frankfurt:A8D | Frankfurt | Germany | EUR |
| Hamburg:A8D | Hamburg | Germany | EUR |
| Munich:A8D | Munich | Germany | EUR |
| Stuttgart:A8D | Stuttgart | Germany | EUR |
| Tradegate:A8D | Tradegate | Germany | EUR |
Valuation
EV/sales 39.2× against a median of 128×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €46.05M EUR
- P/E
- Loss
- EV/sales
- 39.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 61.3%
- Operating margin
- −103.7%
- Net margin
- −132.6%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.36M | n/a | 373× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.77M | US$51.65M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| EyeGene, Inc. · KRX:185490 | US$55.23M | US$26.50M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Median of the others | US$55.11M | US$29.75M | 128× | 1.8× | −217.3% | 0.0× | 1.02 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.49 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.15 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Stéphane LEDERMANN | Chairman and Chief Executive Officer |
| Laurent GUY | Chief Financial Officer |
| Christian FASSOTTE | Global Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Stéphane LEDERMANN | Chairman and Chief Executive Officer |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 33 slides | January 2026 |
| Investor Presentation (March 2025) | Investor deck | 59 slides | March 2025 |
| Corporate Update (December 2024) | Corporate update | 35 slides | December 2024 |
| Investor Presentation (July 2024) | Investor deck | 46 slides | July 2024 |
| Investor Presentation (April 2024) | Investor deck | 37 slides | April 2024 |
| Investor Presentation (February 2023) | Investor deck | 28 slides | February 2023 |
| Corporate Update (February 2022) | Corporate update | 27 slides | Feb 28, 2022 |
| Investor Presentation (January 2022) | Investor deck | 60 slides | January 2022 |
| Investor Presentation (October 2021) | Investor deck | 61 slides | October 2021 |
| Technical Presentation (May 2021) | Technical | 28 slides | May 25, 2021 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AB Science Webconference: Masitinib in Pancreatic Cancer (December 2020) | Conference | 22 slides | Dec 11, 2020 |
| Investor Presentation (December 2020) | Investor deck | 49 slides | December 2020 |
| MSVirtual2020 (ACTRIMS-ECTRIMS) (November 2020) | Conference | 16 slides | November 2020 |
| Investor Presentation (September 2020) | Investor deck | 35 slides | September 2020 |
| Corporate Update (May 2020) | Corporate update | 23 slides | May 11, 2020 |
| Technical Presentation (March 2020) | Technical | 36 slides | Mar 6, 2020 |
| Investor Presentation (January 2020) | Investor deck | 39 slides | January 2020 |
| AB Science Webconference: Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids (December 2019) | Conference | 27 slides | Dec 2, 2019 |
| Corporate Update (November 2019) | Corporate update | 46 slides | Nov 20, 2019 |
| Investor Presentation (2018) | Investor deck | 17 slides | Oct 4, 2018 |
| Advances in Alzheimer Therapy (AAT) 2016 | Conference | 34 slides | March 2016 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares with share warrants attached (ABSA) Closed: €14.2M raised · €0.61 a share · 1 warrant at €1 for 60 months Buyers: Existing long-term investor (EUR 12 million); Stéphane Ledermann Insiders: The CEO, Stéphane Ledermann, also contributed to the financing Use of proceeds: Fund R&D programs, mainly AB8939 in acute myeloid leukemia, masitinib in ALS, and nearer-term value-creation projects | Aug 10, 2026 | US$16.4M |
| Private placement of new ordinary shares with share warrants attached (ABSA) Announced: €3.2M · €0.94 a share · Warrants at €1.3 for 48 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Finance ongoing activities, with a focus on the clinical development of the AB8939 program | Apr 29, 2026 | US$3.74M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €2.8M raised · €1.13 a share · Warrants at €1.72 for 60 months Use of proceeds: Finance ongoing activities, focusing on clinical development of AB8939: finish phase 1 and launch an AML expansion study | Oct 17, 2025 | US$3.27M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €2.55M raised · €1.12 a share · Warrants at €1.71 for 60 months Use of proceeds: To finance ongoing activities, with a focus on the clinical development of the AB8939 program | Aug 4, 2025 | US$2.94M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €1.93M raised · €1.17 a share · Warrants at €1.78 for 60 months Use of proceeds: Finance ongoing activities, with a focus on clinical development of the AB8939 program | Jul 8, 2025 | US$2.25M |
| Private placement of new shares Closed: €1.8M in the latest tranche · €1.17 a share · Warrants at €1.79 for 60 months · Maxim Group, LLC Dealers: Maxim Group, LLC (lead) Use of proceeds: Strengthens the cash position and covers financing needs in 2025 and beyond the next 12 months | May 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 1.07M | 970.0K | 958.0K | 1.61M | 1.58M | 1.57M | 1.70M | 1.74M | 1.51M |
| Cost of revenue | 454.0K | -176.0K | 383.0K | 31.0K | 111.0K | 69.0K | 181.0K | 248.0K | 121.0K | 453.0K |
| Gross profit | 720.0K | 1.25M | 587.0K | 927.0K | 1.50M | 1.51M | 1.39M | 1.45M | 1.62M | 1.05M |
| Research and development | 2.09M | 3.94M | 13.9M | 13.3M | 11.2M | 12.8M | 15.6M | 26.9M | 26.7M | 27.9M |
| Selling, general and administrative | 1.39M | 1.81M | 3.02M | 1.87M | 3.58M | 2.64M | 2.26M | 2.39M | 2.27M | 2.48M |
| Operating income | -1.22M | -6.08M | -13.4M | -15.9M | -13.8M | -14.7M | -17.5M | -28.9M | -28.4M | -30.2M |
| Depreciation and amortization | 3.00K | 667.0K | 2.27M | 805.0K | 886.0K | 1.15M | 853.0K | 669.0K | 436.0K | 611.0K |
| EBITDA | -1.21M | -5.42M | -11.2M | -15.1M | -12.9M | -13.6M | -16.6M | -28.3M | -28.0M | -29.6M |
| Interest expense | 1.41M | 1.23M | 3.96M | 3.41M | 56.0K | 157.0K | 17.0K | 0 | 0 | 474.0K |
| Income before tax | -3.41M | -7.83M | -12.0M | -13.6M | -14.4M | -15.0M | -21.7M | -26.1M | -27.1M | -27.7M |
| Income tax | -1.86M | -2.32M | -1.94M | 4.00K | 36.0K | 8.00K | 4.00K | 4.00K | 6.00K | -11.0K |
| Net income | -1.56M | -7.83M | -10.0M | -13.6M | -14.5M | -15.0M | -21.7M | -26.1M | -27.1M | -27.7M |
| Earnings per share, basic | -0.03 | -0.15 | -0.20 | -0.29 | -0.30 | -0.34 | -0.55 | -0.69 | -0.75 | -0.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.2M | 7.99M | 6.07M | 7.27M | 8.72M | 20.7M | 5.70M | 11.6M | 38.8M | 19.8M |
| Short-term investments | 0 | 0 | 0 | 0 | 0 | 6.00M | 10.0M | 0 | ||
| Receivables | 3.49M | 827.0K | 236.0K | 12.5M | 8.36M | 4.86M | 8.16M | 236.0K | 449.0K | 428.0K |
| Inventory | 151.0K | 184.0K | 336.0K | 456.0K | 141.0K | 79.0K | 230.0K | 153.0K | 159.0K | 134.0K |
| Current assets | 14.2M | 14.5M | 19.4M | 20.9M | 18.2M | 26.3M | 14.1M | 20.7M | 48.6M | 36.1M |
| Property, plant and equipment | 899.0K | 785.0K | 1.27M | 1.59M | 1.82M | 2.17M | 153.0K | 171.0K | 214.0K | |
| Total assets | 24.5M | 23.2M | 25.5M | 23.8M | 21.3M | 29.7M | 17.7M | 22.5M | 50.6M | 38.0M |
| Accounts payable | 9.30M | 6.00M | 11.1M | 7.36M | 11.4M | 13.3M | 15.0M | 15.0M | 15.5M | 16.6M |
| Current liabilities | 14.8M | 20.4M | 18.7M | 23.1M | 17.5M | 22.6M | 19.5M | 19.2M | 18.7M | 20.3M |
| Long-term debt | 17.9M | 14.0M | 16.6M | 18.6M | 6.69M | 11.1M | 10.2M | 9.34M | 9.33M | 21.7M |
| Total debt | 4.24M | 18.5M | 19.1M | 28.3M | 15.1M | 19.9M | 14.4M | 8.21M | 11.1M | 12.4M |
| Total liabilities | 34.3M | 46.9M | 46.5M | 59.5M | 44.5M | 49.2M | 44.6M | 37.5M | 39.9M | 42.7M |
| Shareholders' equity | -17.2M | -23.8M | -21.0M | -35.7M | -23.2M | -19.5M | -26.8M | -15.0M | 10.7M | -4.71M |
| Shares outstanding | 61.2M | 52.2M | 49.7M | 47.1M | 47.5M | 44.2M | 39.4M | 37.8M | 36.0M | 35.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.29M | 525.0K | -16.9M | -17.5M | -17.2M | -13.5M | -15.2M | -26.8M | -22.9M | -33.5M |
| Capital spending | -282.0K | -155.0K | -345.0K | -644.0K | -564.0K | -370.0K | -390.0K | -484.0K | -503.0K | -524.0K |
| Free cash flow | -4.57M | 370.0K | -17.2M | -18.1M | -17.7M | -13.9M | -15.5M | -27.3M | -23.4M | -34.0M |
| Cash from investing | -224.0K | -136.0K | -614.0K | -360.0K | -590.0K | -277.0K | -432.0K | -490.0K | -495.0K | 5.36M |
| Cash from financing | 6.69M | 1.53M | 16.3M | 16.4M | 5.84M | 28.7M | 9.73M | 61.0K | 42.4M | 32.3M |
| Share buybacks | 3.89M | 11.5M | 4.00K | 4.16M | 22.7M | 9.74M | 61.0K | 42.4M | 32.4M | |
| Change in cash | 2.19M | 1.92M | -1.20M | -1.45M | -11.9M | 15.0M | -5.87M | -27.2M | 19.0M | 4.08M |
Filings
Cap table
Built by 6ix from AB Science SA’s releases · as of Aug 12, 2026
- Common shares
- 96,530,783
- Fully diluted
- 119,809,475
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 96,530,783 | Aug 10, 2026 |
| Warrants | 23,278,692 | Aug 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · €1.00 · expire about Aug 2031 |
| Warrants · €1.72 · expire about Oct 2030 |
| Warrants · €1.71 · expire about Aug 2030 |
| Warrants · €1.78 · expire about Jul 2030 |
| Warrants · €1.79 · expire about May 2030 |
Share count over time
| Count | Shares |
|---|---|
| Aug 10, 2026 | 96,530,783 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christian FASSOTTE | Global Chief Medical Officer · Since at least Nov 5, 2026 |
| Laurent GUY | Chief Financial Officer · Since at least Nov 5, 2026 |
| Stéphane Ledermann | Chairman and Chief Executive Officer · Since at least Oct 9, 2026 |
Log in to ask 6ix AI your own questions about AB Science SA.